ISKJ Stock Overview
Public Joint-Stock Company ‘Human Stem Cells Institute’ operates as a biotech company primarily in Russia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Public Joint-Stock Company "Human Stem Cells Institute" Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₽59.54 |
| 52 Week High | ₽177.00 |
| 52 Week Low | ₽52.52 |
| Beta | 1.41 |
| 11 Month Change | 0% |
| 3 Month Change | 1.43% |
| 1 Year Change | -32.86% |
| 33 Year Change | 391.66% |
| 5 Year Change | 388.03% |
| Change since IPO | 306.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| ISKJ | RU Biotechs | RU Market | |
|---|---|---|---|
| 7D | 0% | 2.9% | 0.6% |
| 1Y | -32.9% | 5.3% | 5.5% |
Return vs Industry: ISKJ underperformed the Russian Biotechs industry which returned -10.3% over the past year.
Return vs Market: ISKJ exceeded the Russian Market which returned -38.2% over the past year.
Price Volatility
| ISKJ volatility | |
|---|---|
| ISKJ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in RU Market | 9.4% |
| 10% least volatile stocks in RU Market | 2.3% |
Stable Share Price: ISKJ has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ISKJ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Prikhodko Viktorovich | hsci.ru |
Public Joint-Stock Company ‘Human Stem Cells Institute’ operates as a biotech company primarily in Russia. The company engages in the drug discovery, research and development, and marketing of proprietary products and services in the field of regenerative medicine; bio-insurance; medical genetics, including reproductive genetics; gene therapy; and biopharmaceutics. It owns and operates Gemabank, a family cord blood stem cell bank in Russia and the CIS; and Reprobank, a reproductive cell and tissue bank for personal storage of reproductive cells and tissues, as well as a sperm/oocyte donation.
Public Joint-Stock Company "Human Stem Cells Institute" Fundamentals Summary
| ISKJ fundamental statistics | |
|---|---|
| Market cap | ₽4.29b |
| Earnings (TTM) | ₽16.94m |
| Revenue (TTM) | ₽1.14b |
253.1x
P/E Ratio3.7x
P/S RatioIs ISKJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISKJ income statement (TTM) | |
|---|---|
| Revenue | ₽1.14b |
| Cost of Revenue | ₽424.68m |
| Gross Profit | ₽719.25m |
| Other Expenses | ₽702.31m |
| Earnings | ₽16.94m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 62.88% |
| Net Profit Margin | 1.48% |
| Debt/Equity Ratio | 103.9% |
How did ISKJ perform over the long term?
See historical performance and comparison